var data={"title":"Demeclocycline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Demeclocycline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5986?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=demeclocycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Demeclocycline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=demeclocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Demeclocycline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157470\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Tetracycline Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157442\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Susceptible infections:</b> Oral: 150 mg 4 times daily or 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>SIADH (off-label use):</b> Oral: 600 to 1,200 mg/day (Goh 2004; Gross 2008, Verbalis 2013). <b>Note:</b> Limited high quality evidence exists to define the clinical role, if any, of demeclocycline in this condition. European clinical practice guidelines recommend against the use of demeclocycline for the management of hyponatremia in patients with SIADH (Spasovski 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157459\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=demeclocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Demeclocycline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Susceptible infections:</b> Oral: Children &gt;8 years and Adolescents: 7 to 13 mg/kg/day (maximum: 600 mg/day) divided every 6-12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157443\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157444\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; dosage adjustment and/or increase in time interval between doses is recommended; use with caution. Tetracyclines are not removed in significant quantities by hemodialysis or peritoneal dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157445\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; dosage adjustment and/or increase in time interval between doses is recommended; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157414\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157398\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157417\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer 1 hour before or 2 hours after food or milk. Administer with adequate amounts of fluid to decrease the risk of esophageal irritation and ulceration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157416\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use of demeclocycline as an antibacterial agent is uncommon; alternative tetracycline agents (eg, doxycycline, minocycline, tetracycline) are generally preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne:</b> Adjunctive therapy in severe acne.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinomycosis:</b> Treatment of actinomycosis caused by <i>Actinomyces israelii</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute intestinal amebiasis:</b> Adjunct to amebicides in acute intestinal amebiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax:</b> Treatment of anthrax due to <i>Bacillus anthracis</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera:</b> Treatment of cholera caused by <i>Vibrio cholerae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Clostridium:</i></b> Treatment of clostridial disease caused by <i>Clostridium</i> spp. when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gram-negative infections:</b> Treatment of infections caused by <i>Escherichia coli</i>, <i>Enterobacter aerogenes</i>, <i>Shigella</i> species, and <i>Acinetobacter</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Listeriosis:</b> Treatment of listeriosis due to <i>Listeria monocytogenes</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic infections:</b> Treatment of inclusion conjunctivitis or trachoma caused by <i>Chlamydia trachomatis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague:</b> Treatment of plague due to <i>Yersinia pestis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Relapsing fever:</b> Treatment of relapsing fever caused by <i>Borrelia recurrentis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b> Treatment of respiratory tract infections caused by <i>Haemophilus influenzae</i>, <i>Klebsiella</i> species, or <i>Mycoplasma pneumoniae</i>; treatment of upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rickettsial infections:</b> Treatment of Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers caused by <i>Rickettsiae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sexually transmitted diseases:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of lymphogranuloma venereum caused by <i>Chlamydia trachomatis</i>; granuloma inguinale caused by <i>Klebsiella granulomatis</i>; chancroid caused by <i>Haemophilus ducreyi</i>; nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i> or <i>Chlamydia trachomatis</i>; when penicillin is contraindicated, uncomplicated urethritis in men caused by <i>Neisseria gonorrhea</i> and other uncomplicated gonococcal infections, infections in women caused by <i>N. gonorrhea</i>, and syphilis caused by <i>Treponema pallidum</i> subspecies pallidum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Demeclocycline is not a recommended alternative for gonorrhea according to the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases guidelines. Consult current guidelines for recommendations (Workowski 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>Staphylococcus aureus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> Treatment of urinary tract infections caused by <i>Klebsiella</i> species</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vincent infection:</b> Treatment of Vincent infection caused by <i>Fusobacterium fusiforme</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws:</b> Treatment of yaws caused by <i>Treponema pallidum</i> subspecies pertenue when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Zoonotic infections:</b> Treatment of psittacosis (ornithosis) caused by <i>Chlamydophila psittaci</i>; tularemia caused by <i>Francisella tularensis</i>; brucellosis caused by <i>Brucella</i> species (in conjunction with streptomycin); bartonellosis caused by <i>Bartonella bacilliformis</i>; infections caused by <i>Campylobacter fetus</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475141\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157405\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Bulging fontanel (infants), dizziness, headache, pseudotumor cerebri (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema multiforme, erythematous rash, maculopapular rash, skin photosensitivity, skin pigmentation, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Microscopic thyroid discoloration (brown/black), nephrogenic diabetes insipidus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, dental discoloration (children &lt;8 years, rare in adults), diarrhea, dysphagia, enterocolitis, esophageal ulcer, glossitis, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Balanitis, inflammatory anogenital lesion (with monilial overgrowth)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, IgA vasculitis, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Superinfection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Exacerbation of systemic lupus erythematosus, Lambert-Eaton syndrome, lupus-like syndrome, polyarthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute renal failure, increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Exfoliative dermatitis, fixed drug eruption, hepatic failure, hepatitis, hepatotoxicity, Stevens-Johnson syndrome, thyroid dysfunction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157420\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to demeclocycline, tetracyclines, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157402\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: May cause dizziness, blurred vision, or lightheadedness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes insipidus syndrome: Dose-dependent nephrogenic diabetes insipidus is common with use (reversible on discontinuation); however, this adverse event of demeclocycline has been used as a therapeutic advantage in the off-label use of hyponatremia associated with SIADH.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intracranial hypertension (eg,  pseudotumor cerebri): Intracranial hypertension (headache, blurred vision) has been associated with use. Usually resolves after discontinuation of treatment; however, permanent sequelae are possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment and/or adjustment to interval frequency recommended. Hepatotoxicity and hepatic failure have been reported rarely with use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment and/or adjustment to interval frequency recommended. Nephrotoxicity has also been reported with use, particularly in the setting of cirrhosis (Sherlock 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299132\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157407\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9328&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Demeclocycline may diminish the therapeutic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Tetracyclines. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide.  Specific dose separation guidelines for other tetracyclines are not presently available.  No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Consider doxycycline as a noninteracting tetracycline derivative. Separate dose administration of oral tetracycline derivative and oral zinc salts by at least 2 hours to minimize interaction.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157433\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Demeclocycline serum levels may be decreased if taken with food, milk, or dairy products. Management: Administer 1 hour before or 2 hours after food, milk, or dairy products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157410\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157423\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Demeclocycline crosses the placenta (Gibbons 1960). Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas 2011). Demeclocycline is not recommended for the treatment of Rocky Mountain Spotted Fever (Biggs 2016), Q fever (Anderson 2013), or anthrax infection (Meaney-Delman 2014) in pregnant women. When systemic antibiotics are needed for dermatologic conditions in pregnant women, other agents are preferred (Kong 2013; Murase 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3414834\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">Tetracyclines are excreted into breast milk. According to the manufacturer, due to the potential for adverse events, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, tetracyclines have generally been avoided in nursing women due to theoretical concerns that they may permanently stain the teeth of the breast-feeding infant (Chung 2002). Some sources note that breast-feeding can continue during tetracycline therapy (Chung 2002; WHO 2002) but recommend use of alternative medications when possible (WHO 2002). Other sources note that short-term exposure may be acceptable; however, long-term use of tetracyclines (eg, for the treatment of acne) should be avoided in breast-feeding women (Pugashetti 2013). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (Chung 2002; WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157424\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Due to potential for decreased absorption, administer 1 hour before or 2 hours after food or milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157412\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal and hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157401\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane; inhibits the action of ADH in patients with chronic SIADH</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157419\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: SIADH: 2 to 5 days (Sherlock 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: 66% (Agwuh 2006); extent of absorption is reduced by food and by certain antacids and dairy products containing aluminum, calcium, magnesium, or iron </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 1.7 L/kg (Agwuh 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~40% to 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 10 to 16 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (44% as unchanged drug); feces (13% to 46% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323096\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Demeclocycline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $940.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (48): $819.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038596\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alkonatrem Gel (FR);</li>\n      <li>Declomycin (BD);</li>\n      <li>Demecline (TW);</li>\n      <li>Ledermicina (IT);</li>\n      <li>Ledermycin (AT, AU, BE, GB, GR, IE, IN, LU, NL, NZ, PK);</li>\n      <li>Ledermycine (MT);</li>\n      <li>Perciclina (PT);</li>\n      <li>Unicycline (AE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. <i>J Antimicrob Chemother</i>. 2006;58(2):256-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/16816396/pubmed\" target=\"_blank\" id=\"16816396\">16816396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"173218\"></a>Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion.<i> Ann Intern Med</i>. 1975;83(5):654-656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/173218 /pubmed\" target=\"_blank\" id=\"173218 \">173218 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"170519\"></a>De Troyer A, Demanet JC. Correction of antidiuresis by demeclocycline. <i>N Engl J Med</i>. 1975;293(18):915-918.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/170519 /pubmed\" target=\"_blank\" id=\"170519 \">170519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demeclocycline hydrochloride tablets [prescribing information]. New Castle, DE: Marlex Pharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons RJ, Reichelderfer TE. Transplacental transmission of demethylchlortetracycline and toxicity studies in premature and full term, newly born infants. <i>Antibiotic Med Clin Ther</i>. 1960;7:618-622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/13705067/pubmed\" target=\"_blank\" id=\"13705067\">13705067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15168958\"></a>Goh KP. Management of Hyponatremia. <i>Am Fam Physician</i>. 2004;69(10):2387-2394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/15168958/pubmed\" target=\"_blank\" id=\"15168958\">15168958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18480571\"></a>Gross P. Treatment of Hyponatremia. <i>Intern Med</i>. 2008;47(10):885-891.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/18480571/pubmed\" target=\"_blank\" id=\"18480571\">18480571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/23657872/pubmed\" target=\"_blank\" id=\"23657872\">23657872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/14211113/pubmed\" target=\"_blank\" id=\"14211113\">14211113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant Staphylococcus aureus infections during lactation: safety in breastfeeding infants. <i>Pharmacotherapy</i>. 2009;29(9):1103-1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/19698015/pubmed\" target=\"_blank\" id=\"19698015\">19698015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. <i>Arch Gynecol Obstet</i>. 2011;283(1):7-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/20814687/pubmed\" target=\"_blank\" id=\"20814687\">20814687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15614702\"></a>Pasquale TR, Tan JS. Nonantimicrobial Effects of Antibacterial Agents. <i>Clin Infect Dis</i>. 2005;40(1):127-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/15614702/pubmed\" target=\"_blank\" id=\"15614702\">15614702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/23914887/pubmed\" target=\"_blank\" id=\"23914887\">23914887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20164215\"></a>Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. <i>Eur J Endocrinol</i>. 2010;162(suppl 1):13-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/20164215/pubmed\" target=\"_blank\" id=\"20164215\">20164215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24569125\"></a>Spasovski G, Vanholder R, Allolio B, et al; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia [published correction appears in <i>Eur J Endocrinol</i>. 2014;171(1):X1]. <i>Eur J Endocrinol</i>. 2014;170(3):G1-G47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/24569125/pubmed\" target=\"_blank\" id=\"24569125\">24569125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24074529\"></a>Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. <i>Am J Med</i>. 2013;126(10 suppl 1):S1-S42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/24074529/pubmed\" target=\"_blank\" id=\"24074529\">24074529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/demeclocycline-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs&rdquo;. 2002. Available at: www.who.int/maternal_child_adolescent/documents/55732/en/24074529</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9328 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157470\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F157442\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F157459\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F157443\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F157444\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F157445\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157414\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F157398\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F157417\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F157416\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475141\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157405\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157420\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157402\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299132\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157407\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F157433\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157410\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F157423\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3414834\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F157424\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F157412\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157401\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F157419\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323096\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038596\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9328|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=demeclocycline-patient-drug-information\" class=\"drug drug_patient\">Demeclocycline: Patient drug information</a></li><li><a href=\"topic.htm?path=demeclocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">Demeclocycline: Pediatric drug information</a></li></ul></div></div>","javascript":null}